Affimer reagents have been successfully used to detect and quantify antigens across a broad range of immunoassay platforms. Highly specific Affimer binders can be generated to a wide variety of novel targets and routinely show minimal matrix effects within the assay environment. The application of these binders as capture reagents within an immunoassay can increase the potential specificity and dynamic range of the assay, delivering improved accuracy and the opportunity to multiplex sample analysis.
The ease with which Affimer binders can be formatted enables us to engineer reagents to provide flexibility in assay design and adapt to application requirements.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.
